A Phase I and Pharmacodynamic Study of the Histone deacetylase inhibitor Belinostat plus Azacitidine in Advanced Myeloid Neoplasia

BACKGROUND: We hypothesized that targeting two mechanisms of epigenetic silencing would be additive or synergistic with regard to expression of specific target genes. The primary objective of the study was to establish the maximum tolerated dose (MTD) of belinostat in combination with a fixed dose o...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Invest New Drugs
Main Authors: Odenike, Olatoyosi, Halpern, Anna, Godley, Lucy A., Madzo, Jozef, Karrison, Theodore, Green, Margaret, Fulton, Noreen, Mattison, Ryan J., Yee, Karen. W. L., Bennett, Meghan, Koval, Gregory, Malnassy, Gregory, Larson, Richard A., Ratain, Mark J., Stock, Wendy
Formato: Artigo
Idioma:Inglês
Publicado em: 2014
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4390421/
https://ncbi.nlm.nih.gov/pubmed/25483416
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-014-0194-2
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados